Subcutaneous panniculitis-like T-cell lymphoma with hemophagocytic lymphohistiocytosis in a psoriasis patient after sequential biologics including extended brodalumab: a case report.

Biologic therapies have revolutionized psoriasis management, but they have also raised concerns about potential unusual adverse effects. We think this represents the first detailed case of subcutaneous panniculitis-like T-cell lymphoma with hemophagocytic lymphohistiocytosis in a psoriasis patient, confirmed clinically and histopathologically, occurring after 9 months of brodalumab treatment following multiple biologic switches. The patient's development of subcutaneous panniculitis-like T-cell lymphoma during an extended period on brodalumab, compared to other biologics, underscores the need for awareness of potential rare complications associated with this therapy.